Loading...
OTCM
WXIBF
Market cap19bUSD
Jul 09, Last price  
4.60USD
1D
0.00%
1Q
0.00%
IPO
-33.33%
Name

WuXi Biologics (Cayman) Inc

Chart & Performance

D1W1MN
OTCM:WXIBF chart
P/E
26.34
P/S
5.93
EPS
1.18
Div Yield, %
Shrs. gr., 5y
-0.16%
Rev. gr., 5y
31.17%
Revenues
21.79b
+16.68%
331,850,000557,042,000989,029,0001,618,829,0002,534,453,0003,983,687,0005,612,384,00010,290,050,00015,268,660,00017,034,255,00018,675,371,00021,790,018,000
Net income
4.91b
+46.25%
41,978,00044,509,000141,096,000252,628,000630,592,0001,013,805,0001,688,886,0003,388,478,0004,420,286,0003,399,729,0003,356,081,0004,908,343,000
CFO
6.39b
+22.45%
21,505,000107,150,00081,921,000360,280,000761,607,0001,208,079,0001,881,276,0003,431,258,0005,541,673,0004,667,712,0005,217,257,0006,388,476,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Headquartered in Wuxi, China, and established in 2014, WuXi Biologics (Cayman) Inc. delivers a comprehensive, integrated suite of services spanning the entire biologics lifecycle, from initial discovery through development to large-scale manufacturing. The company's operations have a global footprint, serving clients across the People's Republic of China, North America, Europe, and other international regions. Its diversified offerings also include specialized consultation in biopharmaceutical technology, international sales contracting, the development and deployment of advanced testing methodologies, and robust marketing and sales support. Furthermore, WuXi Biologics is involved in providing dedicated biologics clinical and manufacturing services, the production and distribution of various medical products, contract development and manufacturing (CDMO) for vaccines and associated businesses, and acting as a supplier of key materials. The firm maintains strategic partnerships with notable entities such as ImmuneOncia Therapeutics, Legochem Biosciences Inc., Worg Pharma, OncoC4, and Exelixis Inc.
IPO date
Jun 13, 2017
Employees
12,397
Domiciled in
CN
Incorporated in
KY

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT